---
title: "Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294692454.md"
description: "A worldwide clinical trial has been structured to assess the effects of pemvidutide on enhancing fibrosis, resolving MASH, and improving overall clinical outcomes. This study will involve a significant number of participants from different regions, with the aim of obtaining comprehensive data on the potential benefits of this treatment."
datetime: "2026-08-03T12:03:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294692454.md)
  - [en](https://longbridge.com/en/news/294692454.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294692454.md)
generator: "portal-rs"
---

# Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH

A worldwide clinical trial has been structured to assess the effects of pemvidutide on enhancing fibrosis, resolving MASH, and improving overall clinical outcomes. This study will involve a significant number of participants from different regions, with the aim of obtaining comprehensive data on the potential benefits of this treatment.

### Related Stocks

- [ALT.US](https://longbridge.com/en/quote/ALT.US.md)

## Related News & Research

- [Altimmune CEO Jerome Benedict Durso acquires USD 44,250 in common shares](https://longbridge.com/en/news/295838846.md)
- [Altimmune reports positive Phase 2 RECLAIM topline results for pemvidutide in AUD](https://longbridge.com/en/news/294056102.md)
- [Altimmune's drug meets main goal of mid-stage study for alcohol use disorder](https://longbridge.com/en/news/294056614.md)
- [Altimmune’s Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial](https://longbridge.com/en/news/294079208.md)
- [Altimmune Sets Pemvidutide’s Phase 3 MASH Playbook as AUD Data Near](https://longbridge.com/en/news/289332663.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**